Table 1.

Sensitivity of IGROV-1, IGROV-1/OHP, and IGROV-1/Pt1 cells to platinum compounds, to the EGFR inhibitor gefitinib, and to the MEK1/2 inhibitor U0126

DrugIC50 (μmol/L)
IGROV-1IGROV-1/OHPIGROV-1/Pt1
cDDP (1 h)7.3 ± 1.650.96 ± 9.0 (7)*94.1 ± 14.0 (13)*
OHP (1 h)12.7 ± 3.1928.5 ± 78.0 (73)*171.5 ± 0.2 (13)*
Gefitinib (72 h)0.18 ± 0.053.34 ± 0.9 (19)*9.12 ± 2.0 (51)*
U0126 (72 h)0.025 ± 0.0015.95 ± 3.1 (238)*8.4 ± 1.8 (336)*
  • NOTE: Cell sensitivity to drug was assessed by growth inhibition assay. Twenty-four hours after seeding, cells were exposed for 1 h to cDDP or OHP and were counted 72 h after treatment. For gefitinib and U0126, treatment was for 72 h and cells were counted at the end of treatment. Mean ± SD of three to six independent experiments.

  • * Degree of resistance, ratio between the IC50 value of resistant and parental cells.